Dual-subtype Feline Immunodeficiency Virus Vaccine Provides 12 Months of Protective Immunity Against Heterologous Challenge

Overview

Journal J Feline Med Surg

Specialty Veterinary Medicine

Date 2010 Feb 20

PMID 20167521

Citations 8

Authors

Chengjin Huang

Douglas Conlee

Michael Gill

Hsien-Jue Steve Chu

Affiliations

Soon will be listed here.

Abstract

The duration of immunity of the dual-subtype feline immunodeficiency virus (FIV) vaccine, Fel-O-Vax FIV, for protection against subtype-B FIV was assessed in this study. Vaccinated cats along with controls were challenged with FIV(FC1), a subtype-B FIV strain, 54 weeks after the final vaccination, and monitored for 46-48 weeks for provirus and viral RNA in peripheral blood, provirus in lymphoid organs, and CD4:CD8 ratios. Results of provirus detection in peripheral blood and lymphoid organs and plasma viral RNA loads showed that 10/14 vaccinated cats were fully protected for 48 weeks against infection with FIV(FC1) whereas 5/5 controls were persistently infected with FIV(FC1). CD4:CD8 inversions were noted in association with FIV infection and viral loads were not significantly different between FIV infected controls and the unprotected vaccinated animals.

Citing Articles

Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.

Westman M, Coggins S, van Dorsselaer M, Norris J, Squires R, Thompson M Aust Vet J. 2022; 100(8):345-359.

PMID: 35578381 PMC: 9546031. DOI: 10.1111/avj.13166.

Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax FIV).

Westman M, Yang D, Green J, Norris J, Malik R, Parr Y Viruses. 2021; 13(3).

PMID: 33809232 PMC: 7998844. DOI: 10.3390/v13030470.

Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.

Sahay B, Yamamoto J Viruses. 2018; 10(5).

PMID: 29789450 PMC: 5977270. DOI: 10.3390/v10050277.

The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?.

Hosie M, Techakriengkrai N, Beczkowski P, Harris M, Logan N, Willett B Vet Sci. 2017; 4(1).

PMID: 29056666 PMC: 5606627. DOI: 10.3390/vetsci4010007.

Duration of antibody response following vaccination against feline immunodeficiency virus.

Westman M, Malik R, Hall E, Harris M, Hosie M, Norris J J Feline Med Surg. 2016; 19(10):1055-1064.

PMID: 27770018 PMC: 11110993. DOI: 10.1177/1098612X16673292.

References

Phadke A, de la Concha-Bermejillo A, Wolf A, Andersen P, Baladandayuthapani V, Collisson E . Pathogenesis of a Texas feline immunodeficiency virus isolate: an emerging subtype of clade B. Vet Microbiol. 2006; 115(1-3):64-76. DOI: 10.1016/j.vetmic.2006.02.012. View

Hohdatsu T, Okada S, Motokawa K, Aizawa C, Yamamoto J, Koyama H . Effect of dual-subtype vaccine against feline immunodeficiency virus infection. Vet Microbiol. 1998; 58(2-4):155-65. PMC: 7117228. DOI: 10.1016/s0378-1135(97)00164-8. View

Pu R, Coleman J, Coisman J, Sato E, Tanabe T, Arai M . Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate. J Feline Med Surg. 2005; 7(1):65-70. PMC: 10911555. DOI: 10.1016/j.jfms.2004.08.005. View

Pu R, Coleman J, Omori M, Arai M, Hohdatsu T, Huang C . Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS. 2001; 15(10):1225-37. DOI: 10.1097/00002030-200107060-00004. View

Tompkins M, Ogilvie G, Franklin R, Kelley K, Tompkins W . Induction of IL-2 and lymphokine activated killer cells in the cat. Vet Immunol Immunopathol. 1987; 16(1-2):1-10. DOI: 10.1016/0165-2427(87)90169-3. View

Huang C, Conlee D, Loop J, Champ D, Gill M, Chu H . Efficacy and safety of a feline immunodeficiency virus vaccine. Anim Health Res Rev. 2005; 5(2):295-300. DOI: 10.1079/ahr200487. View

Klonjkowski B, Klein D, Galea S, Gavard F, Monteil M, Duarte L . Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS. Vaccine. 2008; 27(6):928-39. DOI: 10.1016/j.vaccine.2008.11.086. View

Levy J, Scott H, Lachtara J, Crawford P . Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. J Am Vet Med Assoc. 2006; 228(3):371-6. DOI: 10.2460/javma.228.3.371. View

Willett B, Hosie M, Callanan J, Neil J, Jarrett O . Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. Immunology. 1993; 78(1):1-6. PMC: 1421779. View

10.

Omori M, Pu R, Tanabe T, Hou W, Coleman J, Arai M . Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine. 2004; 23(3):386-98. DOI: 10.1016/j.vaccine.2004.05.032. View

11.

Uhl E, Martin M, Coleman J, Yamamoto J . Advances in FIV vaccine technology. Vet Immunol Immunopathol. 2008; 123(1-2):65-80. PMC: 3581037. DOI: 10.1016/j.vetimm.2008.01.030. View

12.

Kusuhara H, Hohdatsu T, Okumura M, Sato K, Suzuki Y, Motokawa K . Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol. 2005; 108(3-4):155-65. DOI: 10.1016/j.vetmic.2005.02.014. View

13.

Steinrigl A, Klein D . Phylogenetic analysis of feline immunodeficiency virus in Central Europe: a prerequisite for vaccination and molecular diagnostics. J Gen Virol. 2003; 84(Pt 5):1301-1307. DOI: 10.1099/vir.0.18736-0. View